Retatrutide HA - 12MG

Log in to view pricing Apply for provider account
Retatrutide HA - 12MG

Product Overview

GLP-1 R Weight Loss

GLP-1 R 1 is a triple hormone receptor agonist targeting the GLP-1, GIP, and glucagon receptors, developed for chronic weight management and metabolic health in adults with overweight or obesity.[1][2][3][4]

Mechanism of Action:

GLP-1 R activates GLP-1, GIP, and glucagon receptors, resulting in synergistic effects on appetite suppression, energy expenditure, and fat metabolism. GLP-1 receptor activation reduces appetite and caloric intake via central hypothalamic pathways, delays gastric emptying, and enhances glucose-dependent insulin secretion.[5] GIP receptor activation further potentiates insulin secretion and may enhance the weight loss and metabolic effects of GLP-1 agonism.[2][3] Glucagon receptor activation increases energy expenditure and promotes lipolysis and fat oxidation, contributing to greater reductions in body weight and adiposity.[2][3][5]

Efficacy for Weight Loss and Body Composition:

In a phase 2 trial, GLP-1 R once weekly resulted in a mean weight loss of 24.2% at 48 weeks in adults with obesity, compared to 2.1% with placebo.[1] Network meta-analyses confirm that GLP-1 R achieves greater weight loss than GLP-1 S, GLP-1 T, and other GLP-1 or dual agonists, with mean reductions in body weight of 22–26% in non-diabetic populations.[6][7][8][9][10][1][2][3][11][12][4] The proportion of patients achieving ≥15% weight loss is also highest with GLP-1 R (up to 83% at 48 weeks).[1] Body composition studies show that GLP-1 R -induced weight loss is primarily due to reductions in total and visceral fat mass, with a similar proportion of lean mass loss to other obesity pharmacotherapies.[13]

Appetite Regulation and Energy Balance:

GLP-1 R reduces appetite and caloric intake through central and peripheral mechanisms, including modulation of hypothalamic satiety centers and delayed gastric emptying. Glucagon receptor activation increases basal metabolic rate and energy expenditure, further supporting negative energy balance and sustained weight loss.[2][3][5]

Metabolic Health:

GLP-1 R improves multiple metabolic parameters, including glycemic control (HbA1c reduction up to 2.0% in type 2 diabetes), fasting plasma glucose, and lipid profiles.[14][8][10][1][13][2][3][11][15] It also reduces liver steatosis and may benefit diabetic kidney disease.[15] Blood pressure reductions and improvements in cardiovascular risk factors have been observed, consistent with other incretin-based therapies.[14][8][10][1][13][2][3][11]

Safety and Tolerability:

The most common adverse events are mild-to-moderate gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), which are dose-dependent and can be mitigated by gradual dose escalation.[6][7][14][8][1][2][3][4] Serious adverse events and hypoglycemia are rare, and the overall safety profile is similar to other GLP-1-based agents.[6][7][14][8][1][2][3][4]

Summary:

GLP-1 R is a next-generation triple agonist that provides superior weight loss, appetite suppression, fat mass reduction, and metabolic improvements compared to currently available GLP-1 and dual agonists. Its mechanism of action—targeting GLP-1, GIP, and glucagon receptors—enables synergistic effects on energy balance and metabolic health, positioning it as a leading candidate for obesity and metabolic disease management.[6][7][14][8][9][10][1][13][2][3][11][5][12][16][4][15][17]

References

  1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. Jastreboff AM, Kaplan LM, Frías JP, et al. The New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
  2. Retatrutide-a Game Changer in Obesity Pharmacotherapy. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Biomolecules. 2025;15(6):796. doi:10.3390/biom15060796.
  3. The Promise of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) for the Treatment of Obesity: A Look at Phase 2 and 3 Pipelines. Madsbad S, Holst JJ. Expert Opinion on Investigational Drugs. 2025;34(3):197-215. doi:10.1080/13543784.2025.2472408.
  4. Retatrutide Showing Promise in Obesity (And Type 2 Diabetes). Doggrell SA. Expert Opinion on Investigational Drugs. 2023 Jul-Dec;32(11):997-1001. doi:10.1080/13543784.2023.2283020.
  5. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Moiz A, Filion KB, Tsoukas MA, et al. The American Journal of Medicine. 2025;138(6):934-940. doi:10.1016/j.amjmed.2025.01.021.
  6. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Sinha B, Ghosal S. Obesity (Silver Spring, Md.). 2025;. doi:10.1002/oby.24360.
  7. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Moiz A, Filion KB, Toutounchi H, et al. Annals of Internal Medicine. 2025;178(2):199-217. doi:10.7326/ANNALS-24-01590.
  8. Seven Glucagon-Like Peptide-1 Receptor Agonists and Polyagonists for Weight Loss in Patients With Obesity or Overweight: An Updated Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Xie Z, Zheng G, Liang Z, et al. Metabolism: Clinical and Experimental. 2024;161:156038. doi:10.1016/j.metabol.2024.156038.
  9. Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis. Zhang S, Yu B, Xu J, et al. Diabetes Technology & Therapeutics. 2025;27(6):422-429. doi:10.1089/dia.2024.0533.
  10. Comparative Efficacy of Incretin Drugs on Glycemic Control, Body Weight, and Blood Pressure in Adults With Overweight or Obesity and With/Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Liu S, Hu J, Zhao C, Liu H, He C. Frontiers in Endocrinology. 2025;16:1513641. doi:10.3389/fendo.2025.1513641.
  11. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-Analysis, and Meta-Regression of 47 Randomized Controlled Trials. Wong HJ, Sim B, Teo YH, et al. Diabetes Care. 2025;48(2):292-300. doi:10.2337/dc24-1678.
  12. Medications for Obesity: A Review. Gudzune KA, Kushner RF. JAMA. 2024;332(7):571-584. doi:10.1001/jama.2024.10816.
  13. Effects of Retatrutide on Body Composition in People With Type 2 Diabetes: A Substudy of a Phase 2, Double-Blind, Parallel-Group, Placebo-Controlled, Randomised Trial. Coskun T, Wu Q, Schloot NC, et al. The Lancet. Diabetes & Endocrinology. 2025;:S2213-8587(25)00092-0. doi:10.1016/S2213-8587(25)00092-0.
  14. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA. Rosenstock J, Frias J, Jastreboff AM, et al. Lancet (London, England). 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X.
  15. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial. Sanyal AJ, Kaplan LM, Frias JP, et al. Nature Medicine. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2.
  16. What Is the Pipeline for Future Medications for Obesity?. Melson E, Ashraf U, Papamargaritis D, Davies MJ. International Journal of Obesity (2005). 2025;49(3):433-451. doi:10.1038/s41366-024-01473-y.
  17. The Weight-Loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-Diabetic Individuals With Overweight or Obesity: A Systematic Review With Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Liu Y, Ruan B, Jiang H, et al. The American Journal of Clinical Nutrition. 2023;118(3):614-626. doi:10.1016/j.ajcnut.2023.04.017.

All information provided is for research purposes only.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.